Literature DB >> 35101647

Neuropeptide B/W receptor 1 peptidomimetic agonists: Structure-activity relationships and plasma stability.

Thuy Nguyen1, Ann M Decker2, Rodney W Snyder2, Emma C Tonetti2, Thomas F Gamage2, Yanan Zhang2.   

Abstract

Neuropeptides B and W (NPB and NPW) are endogenous ligands of the Neuropeptide B/W Receptor 1 (NPBWR1) which has been implicated in a wide range of functions including regulation of pain and energy homeostasis. There is currently little information on the structure-activity relationships (SAR) of these two neuropeptides. In a quest to develop stable and potent NPBWR1 peptidomimetic agonists, we performed systematic SAR by truncation, Alanine/Glycine and d-amino acid scans, and replacement with unnatural amino acids. Evaluation in the NPBWR1 calcium assay revealed that the C-terminal GRAAGLL and N-terminal WYK regions constitute the two-epitope pharmacophore for NPBWR1 agonism. Replacement of the N-terminal Trp with its desaminoTrp residue resulted in compound 30 which exhibited nanomolar potency comparable to the endogenous NPB at NPBWR1 (Calcium assay: EC50 = 8 nM vs. 13 nM, cAMP assay: 2.7 nM vs 3.5 nM) and enhanced metabolic stability against rat plasma (39.1 min vs. 11.9 min).
Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  G protein coupled receptor; Neuropeptide B; Neuropeptide B/W receptor 1; Neuropeptide W; Plasma stability; Structure-activity relationship

Mesh:

Substances:

Year:  2022        PMID: 35101647      PMCID: PMC8891040          DOI: 10.1016/j.ejmech.2022.114149

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  37 in total

1.  Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7).

Authors:  Remond Moningka; F Anthony Romero; Nicholas B Hastings; Zhiqiang Guo; Ming Wang; Jerry Di Salvo; Ying Li; Dorina Trusca; Qiaoling Deng; Vincent Tong; Jenna L Terebetski; Richard G Ball; Feroze Ujjainwalla
Journal:  Bioorg Med Chem Lett       Date:  2020-09-06       Impact factor: 2.823

Review 2.  An overview of Ca2+ mobilization assays in GPCR drug discovery.

Authors:  Qiang Ma; Lingyan Ye; Hongxia Liu; Ying Shi; Naiming Zhou
Journal:  Expert Opin Drug Discov       Date:  2017-03-17       Impact factor: 6.098

3.  Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

Authors:  David A Perrey; Ann M Decker; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-11-20       Impact factor: 4.418

Review 4.  Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.

Authors:  Brad R Green; Misty Smith; Karen L White; H Steve White; Grzegorz Bulaj
Journal:  ACS Chem Neurosci       Date:  2010-11-18       Impact factor: 4.418

5.  Effects of intrathecal and i.c.v. administration of neuropeptide W-23 and neuropeptide B on the mechanical allodynia induced by partial sciatic nerve ligation in rats.

Authors:  T Yamamoto; O Saito; K Shono; S Tanabe
Journal:  Neuroscience       Date:  2005-11-11       Impact factor: 3.590

6.  Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.

Authors:  Thuy Nguyen; Thomas F Gamage; Ann M Decker; Daniel Barrus; Tiffany L Langston; Jun-Xu Li; Brian F Thomas; Yanan Zhang
Journal:  J Med Chem       Date:  2019-10-24       Impact factor: 7.446

7.  Anti-hyperalgesic effects of intrathecally administered neuropeptide W-23, and neuropeptide B, in tests of inflammatory pain in rats.

Authors:  Tatsuo Yamamoto; Osamu Saito; Koyo Shono; Serabi Tanabe
Journal:  Brain Res       Date:  2005-04-21       Impact factor: 3.252

Review 8.  Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system.

Authors:  Gurminder Singh; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2006-07-17       Impact factor: 8.739

9.  Targeted disruption of GPR7, the endogenous receptor for neuropeptides B and W, leads to metabolic defects and adult-onset obesity.

Authors:  Makoto Ishii; Hong Fei; Jeffrey M Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

10.  Neuropeptide w.

Authors:  Fumiko Takenoya; Haruaki Kageyama; Satoshi Hirako; Eiji Ota; Nobuhiro Wada; Tomoo Ryushi; Seiji Shioda
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.